|
IMU
IMU
IMU - Imuniti - Trial Results and Withdrawal of Cautionary Announcement
IMUNITI HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2004/002282/06)
(JSE Code: IMU & ISIN: ZAE000089199)
("Imuniti" or "the Company")
TRIAL RESULTS AND WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT
TRIAL RESULTS ON IMUNITI PACK
Shareholders are referred to the cautionary announcement published on 14 March
2011.
Imuniti manufactures the Imuniti Nutritional Supplement Combo (INSCP) Pack for
Edge to Edge Global Investments Limited (E2E), the owners of the intellectual
property related to the Imuniti Pack. E2E have advised in a press release the
following:
A clinical trial was conducted on HIV positive patients. The clinical trial was
conducted by Prof Luc Montagnier on the INCSPin conjunction with ARV therapy,
conducted at the Centre Integre de Recherches Biocliniques d`Abidjan
(C.I.R.B.A.), Cote d`Ivoire (under the auspices of UNESCO).
What was clearly observed on this first preliminary trial was the following:
1. Using the new biomarker developed by Professor Montagnier to measure the
remaining viral DNA in the body after ARV treatment and also using the
current standard of measurement namely PCR measurement, the following trend
was observed:
a. The control arm of ARV alone showed no change in any of the markers
requested as per trial protocol.
b. The ARV plus INSCP arm showed a substantial reduction in the viral DNA
in 71% of the patients. Furthermore, PCR showed that 28% of the
patients had viral DNA disappear after three months of INSCP
treatment. This is the first time that this viral DNA has ever been
impacted by a natural combination product.
2. The preliminary results justify further clinical trials with a larger
number of patients. It is also envisaged to use INSCP in HIV positive
naive patients not yet treated by ARVs.
WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT
Shareholders are referred to the cautionary announcement issued on 14 March
2011, and are advised that they no longer need to exercise caution in dealing
with the shares of Imuniti in relation to the prior cautionary announcement.
DURBAN
23 March 2011
Designated Advisor
Arcay Moela (Proprietary) Limited
Date: 23/03/2011 10:35:01 Produced by the JSE SENS Department.
The SENS service is an information dissemination service administered by the
JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or
implicitly, represent, warrant or in any way guarantee the truth, accuracy or
completeness of the information published on SENS. The JSE, their officers,
employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature,
howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
